# US 10,765,660 B2 · Agent containing flavonoid derivatives for treating cancer and inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,765,660 B2
- Document ID: US10765660B2
- Status: Granted
- Kind: B2
- Application number: 15/634,115
- Filed: 2017-06-27
- Published: 2017-12-21
- Granted: 2020-09-08
- Earliest claimed: 2014-11-26
- Applicants: Henry Lowe; Ngeh J. Toyang; Joseph Bryant
- Inventors: Henry Lowe; Ngeh J. Toyang; Joseph Bryant
- Web page: https://patentgrep.com/patent/US10765660B2

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- C07D 311/32: 2,3-Dihydro derivatives, e.g. flavanones
- C07D 311/60: with aryl radicals attached in position 2
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions.

## Claims

### Claim 1

A method of treating a cancer selected from a group consisting of: breast cancer, brain cancer, Kaposi sarcoma, leukemia, lung cancer, melanoma, ovarian cancer, colon cancer, renal cancer, pancreatic cancer, and prostate cancer, the method comprising the steps of:
administering a pharmaceutical composition comprising a compound having the general chemical structure of chemical formula 4:
or any pharmaceutically acceptable salt thereof;
wherein the group R1 is an alkoxy group the groups R2 and R3 are each a methoxy group or a hydroxy group, the group R6 is an alkoxy group, a hydroxyl group or hydrogen, the group R8 is an alkoxy group or hydrogen, the group R9 is a hydroxyl group, bromine, chlorine, flourine, hydroxamic acid group, amine, amide, or hydrogen; and
wherein A-B is a single bond representing a flavanone flavonoid.

### Claim 2 (depends on 1)

The method of claim 1, wherein said compound is administered in a concentration within a range of from 0.1 to 500 mg between 1-6 times per day.

### Claim 3 (depends on 1)

The method of claim 1, wherein said compound is administered using a method selected from the group consisting of: rectal administration, intravenous administration via the epidural muscle, subcutaneous administration, intrauterine administration, via intracerebroventricular injections, and topically.

### Claim 4 (depends on 1)

The method of claim 1, wherein said compound is administered orally.

### Claim 5 (depends on 1)

The method of claim 1, wherein said compound is administered in a form selected from the group consisting of: powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and suppositories.

### Claim 6 (depends on 1)

The method of claim 1, wherein said compound is administered in a formulation comprising a carrier, said carrier being selected from the group consisting of: lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpynolidone, water, methyl benzoate, propyl benzoate, talc, magnesium stearate, and mineral oil.

### Claim 7

A pharmaceutical composition for treating a cancer selected from a group consisting of: breast cancer, brain cancer, Kaposi sarcoma, leukemia, lung cancer, melanoma, ovarian cancer, colon cancer, renal cancer, pancreatic cancer, and prostate cancer, said pharmaceutical composition comprising a compound having the general chemical structure of chemical formula 4:
or any pharmaceutically acceptable salt thereof;
wherein the group R1 is an alkoxy group, the groups R2 and R3 are each a methoxy group or a hydroxy group, the group R6 is an alkoxy group, a hydroxyl group or hydrogen, the group R8 is an alkoxy group or hydrogen, the group R9 is a hydroxyl group, bromine, chlorine, fluorine, hydroxamic acid group, amine, amide, or hydrogen; and
wherein A-B is a single bond representing a flavanone flavonoid.